Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Authors:
- 1 September 2017
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 403, 339-353
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation (NRF) (2015M3A9C4075818, 2015R1A2A1A10054108, 2014009392, 2014M3C1A3051476)
- Korea Health Technology R&D project
- Ministry of Health and Welfare (HI15C0554)
This publication has 56 references indexed in Scilit:
- YB-1: oncoprotein, prognostic marker and therapeutic target?Biochemical Journal, 2012
- Molecular Mechanisms of Tumor AngiogenesisGenes & Cancer, 2011
- Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid CellsCancer Cell, 2011
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- The biology of VEGF and its receptorsNature Medicine, 2003
- Angiogenesis and Tumor MetastasisAnnual Review of Medicine, 1998
- European standards for antibiotic susceptibility testing: Towards a theoretical consensusEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990